Atsena Therapeutics
atsenatx.com
Actively hiring
Biotechnology
Clinical Trial Services (CRO)
Cell & Gene Therapy
As featured in
Follow
Overview
News
Salaries
Products
People
Growth
Offices
Financials
Funding and backers
Backers
1
Lightstone Ventures
Momentum
0/100
no fresh signals
Last sign of life
this month
a posting or a news item
Backed byfrom the funds' portfolios and accelerator catalogs
Lightstone Ventures Similar startupsby what they do, their industry and backers
Instant Quantification of genetic modifications for Cell and Gene Therapies.
A gene therapy approach to treating chronic, age-related disease. Targeting the root causes of aging to create life-changing treatments for…
ARCUS Genome Editing. At Precision BioSciences, we are using our novel ARCUS genome-editing technology to develop a new class of medicines…
At Arbor Biotechnologies, we develop genetic medicines through our discovery of programmable DNA editors to enable curative outcomes for…
Delivering the next generation of automated cell and gene therapy manufacturing platforms to bring precision medicine to patients.
Metagenomi is an in vivo genome editing company capitalizing on its proprietary technologies to create curative genetic medicines for…
News
Atsena Therapeutics Appoints Matt Pauls to Board of Directors
Matt Pauls brings more than 25 years of biopharma leadership and rare disease clinical development and commercial expertise as Atsena advances its...
Read more
Report
Atsena Therapeutics Appoints Matt Pauls to Board of Directors
Matt Pauls brings more than 25 years of biopharma leadership and rare disease clinical development and commercial expertise as Atsena advances its ocular gene therapy pipeline toward commercialization DURHAM, NC - August 19, 2026 - Atsena Therapeutics, a
Read more
Report
Atsena Therapeutics Receives Orphan Designation from the European Medicines Agency (EMA) for ATSN-101 and ATSN-201
Orphan designation provides market exclusivity and development benefits in the European Union as both programs advance in global pivotal clinical trials DURHAM, NC, July 23, 2026 - Atsena Therapeutics, a clinical-stage gene therapy company focused on usin
Read more
Report
Atsena Therapeutics Selects ATSN-401 Clinical Candidate, a Potential Best-in-Class Gene Therapy for Stargardt Disease
Proprietary dual-vector platform delivers full-length ABCA4, enabled by Atsena's laterally spreading AAV.SPR capsid for delivery to the central retina without foveal detachment ATSN-401 advancing in IND-enabling studies DURHAM, NC, July 9, 2026 - Atsena T
Read more
Report
Atsena Therapeutics Doses First Patient and Reports Rapid Early Enrollment in Pivotal Trial of ATSN-201 for X-Linked Retinoschisis
Enrollment expected to complete Q1 2027; topline results anticipated 1H 2028; BLA filing targeted for 2H 2028 Phase 1/2 data demonstrated ATSN-201's ability to reverse structural damage to the retina and improve vision in patients with XLRS DURHAM, NC, Ju
Read more
Report
Pro access
Upgrade to see all 18 mentions
Upgrade to a paid plan to read every media mention of this company - funding news, awards, product launches and press releases from all the outlets writing about it.
Every media mention and press release
Funding news, awards and product launches
Fresh coverage from every outlet writing about the company
Upgrade now
Cancel anytime. Secure checkout. Instant activation.